The Avandia debate: An unhappy conclusion

Journal of Diabetes

Volumn 2, Issue 4, 2010, Pages 221-222

  Bloomgarden, Zachary ^a   Handelsman, Yehuda ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Journal of Diabetes   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; ROSIGLITAZONE;

CARDIOVASCULAR RISK; DRUG SAFETY; EDITORIAL; EUROPE; FOOD AND DRUG ADMINISTRATION; GLYCEMIC CONTROL; HEART INFARCTION; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; UNITED STATES;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC CARDIOMYOPATHIES; EUROPE; GOVERNMENT AGENCIES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIAZOLIDINEDIONES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 78649681316     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/j.1753-0407.2010.00096.x     Document Type: Editorial

References (17)

1. US Food and Drug Administration. FDA significantly restricts access to the diabetes drug Avandia. Available from: (accessed 27 September 2010).
2. European Medicines Agency. European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim. Available from: (accessed 27 September 2010).
3. Nissen SE, Wolski K,. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007; 356: 2457-71.
4. Diamond GA, Bax L, Kaul S,. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med. 2007; 147: 578-81.
5. Bloomgarden ZT,. The Avandia debate. Diabetes Care. 2007; 30: 2401-8.
6. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for Type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009; 373: 2125-35.
7. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006; 355: 2427-43.
8. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006; 368: 1096-105.
9. Marciniak T,. Cardiovascular Events in the RECORD Trial. Available from: (accessed 27 September 2010).
10. Reaven PD, Moritz TE, Schwenke DC, et al. Intensive glucose-lowering therapy reduces cardiovascular disease events in Veterans Affairs diabetes trial participants with lower calcified coronary atherosclerosis. Diabetes. 2009; 58: 2642-8.
11. Bonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic, severe hypoglycaemia and mortality in Type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ. 2010; 340: b4909.
12. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in Type 2 diabetes. N Engl J Med. 2008; 358: 2545-59.
13. Calles-Escandón J, Lovato LC, Simons-Morton DG, et al. Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care. 2010; 33: 721-7.
14. Riddle MC, Ambrosius WT, Brillon DJ, et al. Epidemiologic relationships between A1c and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care. 2010; 33: 983-90.
15. ACCORD Study Group. Effects of intensive blood-pressure control in Type 2 diabetes mellitus. N Engl J Med. 2010; 362: 1575-85.
16. Bangalore S, Messerli FH, Wun CC, et al. J-Curve revisited: an analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) trial. Eur Heart J. Epub 16 September 2010; doi:.
17. Young LH, Wackers FJ, Chyun DA, et al. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with Type 2 diabetes: the DIAD study. A randomized controlled trial. JAMA. 2009; 301: 1547-55.